Pharmaceutical Executive
July 18, 2005
0
0
Prescription drug abuse nearly doubled over a three-year period, according to a new report. In addition to the statistics that you may have seen elsewhere, the study’s authors recommend ways to curb this trend including submitting all promotional material for controlled drugs to FDA.
July 18, 2005
0
0
Exactly what is Nonarteritic Ischemic Optic Neuropathy and how might it be linked to the use of ED drugs?
July 18, 2005
0
0
The possibility of Brazil compulsorily licensing Abbott Laboratory’s HIV/AIDS treatment Kaletra has re-awakened the debate how the World Trade Organization’s TRIPS agreement should be interpreted for the pharma industry. We asked experts to offer different viewpoints on this issue.